Seattle, WA – Universal Cells Inc. (http://www.universalcells.com) has announced that Dr. Bryan Steadman has joined the company as Chief Technology Officer. He is responsible for the translation of R&D to GMP activities and leadership of the Quality, Regulatory, Process Development and Manufacturing Operations.
“Universal Cells offers the potential to move stem cell therapy from patient specific manufacturing to an off-the-shelf treatment with a significant impact on cost of goods manufactured and supply chain logistics. I am excited to be part of that process.”, said Dr. Steadman.
“We are thrilled to have Bryan join Universal Cells, bringing his vast experience to the company”, said CEO and founder, Dr. Claudia Mitchell “He perfectly fills a key position on our Executive team and someone of his caliber will be a huge asset as we continue to grow.”
Dr. Steadman has a PhD in Zoology and Physiology (Environmental Toxicology) and BS in Microbiology, both from the University of Wyoming.
In total, he has more than 25 years of technical experience having also worked at Merck, Bristol-Meyers Squibb and Allergan in technical and management roles.
Most recently, Bryan was Executive Director Process Development at Amgen transforming biotechnology manufacturing by leveraging new internal and external technology development to create an integrated facility design.
Prior to Amgen, Bryan was VP CMC Operations for LigoCyte, a VC funded biotechnology firm in Bozeman MT that was acquired by Takeda.
Dr. Steadman will be relocating from Bozeman, MT to Seattle WA.